Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Multiple Dose, Crossover Study to Compare the Safety and Pharmacokinetics Between "Rebamipide Sustained Release (SR) 150mg" and "Rebamipide Immediate Release (IR) 100mg" in Healthy Volunteers

NCT04150172 is registered in ClinicalTrials.gov with Korea Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04150172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Multiple Dose, Crossover Study to Compare the Safety and Pharmacokinetics Between "Rebamipide Sustained Release (SR) 150mg" and "Rebamipide Immediate Release (IR) 100mg" in Healthy Volunteers
Lead sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
April 22, 2019
Completion date
May 10, 2019
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers